[go: up one dir, main page]

DK0682524T3 - Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel - Google Patents

Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel

Info

Publication number
DK0682524T3
DK0682524T3 DK94907963T DK94907963T DK0682524T3 DK 0682524 T3 DK0682524 T3 DK 0682524T3 DK 94907963 T DK94907963 T DK 94907963T DK 94907963 T DK94907963 T DK 94907963T DK 0682524 T3 DK0682524 T3 DK 0682524T3
Authority
DK
Denmark
Prior art keywords
bpi
pharmaceutical compositions
relaxant
bactericide
compositions containing
Prior art date
Application number
DK94907963T
Other languages
English (en)
Inventor
Weldon Courtney Mcgregor
James Stubstad
Paul Chang
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Application granted granted Critical
Publication of DK0682524T3 publication Critical patent/DK0682524T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK94907963T 1993-02-02 1994-02-02 Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel DK0682524T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1236093A 1993-02-02 1993-02-02
PCT/US1994/001239 WO1994017819A1 (en) 1993-02-02 1994-02-02 Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant

Publications (1)

Publication Number Publication Date
DK0682524T3 true DK0682524T3 (da) 2002-01-28

Family

ID=21754603

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94907963T DK0682524T3 (da) 1993-02-02 1994-02-02 Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel

Country Status (12)

Country Link
US (5) US5488034A (da)
EP (1) EP0682524B1 (da)
JP (2) JP3946246B2 (da)
CN (1) CN1163264C (da)
AT (1) ATE206308T1 (da)
AU (1) AU695125B2 (da)
CA (1) CA2155005C (da)
DE (1) DE69428521T2 (da)
DK (1) DK0682524T3 (da)
ES (1) ES2164098T3 (da)
PT (1) PT682524E (da)
WO (1) WO1994017819A1 (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
DK0682524T3 (da) * 1993-02-02 2002-01-28 Xoma Technology Ltd Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
AU7175694A (en) 1993-06-17 1995-01-17 Xoma Corporation Lipopolysaccharide binding protein derivatives
AU7330994A (en) * 1993-07-14 1995-02-13 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
WO1995008344A1 (en) * 1993-09-22 1995-03-30 Xoma Corporation Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
US5578572A (en) * 1994-01-14 1996-11-26 Xoma Corporation Anti-gram-positive bacterial methods and materials
WO1995019179A1 (en) * 1994-01-14 1995-07-20 Xoma Corporation Anti-fungal methods and materials
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US5912228A (en) 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
JP2001520631A (ja) * 1995-07-20 2001-10-30 ゾーマ コーポレイション 抗真菌性ペプチド
WO1997017990A1 (en) * 1995-11-14 1997-05-22 Xoma Corporation Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
CA2253837C (en) * 1996-05-10 2002-07-02 Xoma Corporation Therapeutic uses of bpi protein products for human meningococcemia
WO1997044056A1 (en) * 1996-05-23 1997-11-27 Xoma Corporation Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
CA2255865C (en) 1996-05-24 2008-10-14 The Regents Of The University Of Minnesota Synthesis of soluble beta-sheet forming peptides
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
WO1998013069A2 (en) 1996-09-09 1998-04-02 Supratek Pharma, Inc. Fluorinated copolymeric pharmaceutical adjuncts
AU744918B2 (en) * 1996-11-01 2002-03-07 Xoma Corporation Therapeutic uses of BPI protein products in cystic fibrosis patients
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
FR2764800B1 (fr) * 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US5990082A (en) 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
WO2000062795A2 (en) * 1999-04-21 2000-10-26 The Government Of The United States Of America, Represented By The Secretary, Department Of Healt H And Human Services The National Institutes Of Health UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS
US6413537B1 (en) 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
AU2002335815A1 (en) * 2001-10-16 2003-04-28 Rxkinetix, Inc. High-concentration protein formulations and method of manufacture
JP2005536453A (ja) 2002-02-20 2005-12-02 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 部分的なペプチド擬似物及び方法
EP1539212A4 (en) * 2002-07-12 2007-05-02 Medarex Inc METHOD AND COMPOSITIONS FOR PREVENTING OXIDATIVE DEGRADATION OF PROTEINS
DE60317822D1 (de) * 2002-10-29 2008-01-10 Alza Corp Stabilisierte feste polypeptidpartikel
WO2004047862A1 (en) * 2002-11-26 2004-06-10 Eurocine Ab Novel amine-based adjuvant
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
US7741268B2 (en) * 2003-04-02 2010-06-22 Ares Trading S.A. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
US7838721B2 (en) * 2003-04-09 2010-11-23 Paragon Trade Brands, Llc Disposable articles using high column AUL superabsorbents
WO2004112826A1 (en) * 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
US8377459B2 (en) * 2003-07-09 2013-02-19 The Procter & Gamble Company Composition for wet wipes that enhances the efficacy of cleansing while being gentle to the skin
WO2005034999A2 (en) * 2003-10-10 2005-04-21 Bvm Holding Co. Composition comprising association complex of a pharmaceutical and a poloxamer
US7150995B2 (en) * 2004-01-16 2006-12-19 Metrika, Inc. Methods and systems for point of care bodily fluid analysis
ES2526913T3 (es) * 2004-08-04 2015-01-16 Ipsen Biopharm Limited Composición farmacéutica que contiene neurotoxina 2 botulínica
TR201708749T4 (tr) * 2004-08-04 2018-03-21 Ipsen Biopharm Ltd Botuli̇num nörotoksi̇n a2 i̇çeren farmasöti̇k bi̇leşi̇m
US20060173428A1 (en) * 2005-02-02 2006-08-03 Acors Deanna M Absorbent article with logically correlated image and textual graphics
CA2609038A1 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
US20110303542A1 (en) * 2007-08-08 2011-12-15 Advanced Liquid Logic, Inc. Use of Additives for Enhancing Droplet Operations
WO2009034958A1 (ja) * 2007-09-12 2009-03-19 Jsr Corporation タンパク安定化剤およびその製造方法、タンパク安定化剤の使用方法、ならびにタンパク安定化方法
KR101784231B1 (ko) 2008-06-20 2017-11-08 노파르티스 아게 응집이 감소된 면역글로불린
PL2896404T3 (pl) 2009-06-04 2017-12-29 Novartis Ag Sposoby identyfikacji miejsc koniugacji IgG
EP3075386B1 (en) * 2009-06-17 2019-10-16 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
SI3626258T1 (sl) 2010-06-25 2021-11-30 Shire Human Genetic Therapies, Inc. Postopki in sestavki za dovajanje idunorat-2-sulfataze v cžs
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US9090691B2 (en) 2010-09-15 2015-07-28 Applied Molecular Transport Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
GB201116271D0 (en) * 2011-09-21 2011-11-02 Univ Cardiff Dispersion anaesthetic device
MX385898B (es) 2014-05-07 2025-03-18 Applied Molecular Transp Llc Moleculas de fusion derivadas de la toxina colix para suministro oral de una carga biologicamente activa.
HUE059330T2 (hu) 2018-03-08 2022-11-28 Applied Molecular Transport Inc Toxinból származó bejuttatási konstrukciók orális beadásra
CA3093386A1 (en) 2018-03-08 2019-09-12 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
PH12022550330A1 (en) 2019-08-16 2023-02-06 Applied Molecular Transport Inc Compositions, formulations, and interleukin production and purification
CN115666522B (zh) * 2020-03-18 2025-05-27 Gi医诺微新 包含il-2蛋白和cd80蛋白的融合蛋白制剂
MX2023011087A (es) * 2021-03-24 2023-10-02 Japan Chem Res Composicion farmaceutica acuosa o composicion farmaceutica liofilizada estable.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839314A (en) * 1971-06-29 1974-10-01 Baxter Laboratories Inc Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
US4933179A (en) * 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
DE3406497A1 (de) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
US5234683A (en) * 1985-06-18 1993-08-10 Emory University Method of stimulating the immune system
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5152979A (en) * 1986-05-15 1992-10-06 Emory University Method for treating vascular obstructions caused by abnormal cells
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
WO1988006038A1 (en) * 1987-02-20 1988-08-25 Emory University Antiinfective compounds and method of use
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
EP1659132A1 (en) * 1987-08-11 2006-05-24 New York University Biologically active bactericidal/permeability-increasing protein fragments
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH02107163A (ja) * 1988-10-15 1990-04-19 Suntory Ltd 新規なゲル状食品の製造方法
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US4997664A (en) * 1989-09-05 1991-03-05 Bryan Foods, Inc. Method for packaging food products
WO1992009621A1 (en) * 1990-12-03 1992-06-11 New York University Biologically active bactericidal/permeability-increasing protein fragments
IE920860A1 (en) * 1991-03-19 1992-09-23 Cytrx Corp Polyoxypropylene/polyoxyethylene copolymers with improved¹biological activity
US5234908A (en) * 1991-04-12 1993-08-10 Creative Biomolecules, Inc. Method of treating gastrointestinal ulcers with platelet derived growth factor
JPH07502642A (ja) * 1991-09-26 1995-03-23 インサイト　ファーマシューティカルズ，インコーポレイテッド 新規な形態のリポ糖結合性タンパク質（ｌｂｐ）
CA2276548C (en) * 1992-05-19 2001-07-31 Xoma Corporation Improved methods for the preparation of endotoxin-binding proteins
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
DK0682524T3 (da) * 1993-02-02 2002-01-28 Xoma Technology Ltd Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products

Also Published As

Publication number Publication date
CN1127992A (zh) 1996-07-31
DE69428521T2 (de) 2002-05-23
HK1014156A1 (en) 1999-09-24
EP0682524B1 (en) 2001-10-04
JP3946246B2 (ja) 2007-07-18
US5696090A (en) 1997-12-09
ATE206308T1 (de) 2001-10-15
US5488034A (en) 1996-01-30
WO1994017819A1 (en) 1994-08-18
CN1163264C (zh) 2004-08-25
EP0682524A1 (en) 1995-11-22
US6255284B1 (en) 2001-07-03
AU6133094A (en) 1994-08-29
US6066620A (en) 2000-05-23
JP2005145986A (ja) 2005-06-09
CA2155005C (en) 1999-04-06
CA2155005A1 (en) 1994-08-18
JPH10513433A (ja) 1998-12-22
PT682524E (pt) 2002-03-28
AU695125B2 (en) 1998-08-06
DE69428521D1 (de) 2001-11-08
ES2164098T3 (es) 2002-02-16
US5955427A (en) 1999-09-21

Similar Documents

Publication Publication Date Title
DK0682524T3 (da) Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
ATE176482T1 (de) Asp-b28-insulinkristalle
NO952744D0 (no) Cytokinbegrensende midler
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
NO20064159L (no) Nye, biologisk aktive polypeptider, deres fremstilling og farmasoytiske preparater inneholdende polypeptidene
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
EP0783299A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
DK0749317T3 (da) Terapeutiske anvendelser af dimerprodukter af baktericidt/permeabilitetsforøgende protein
IT8323205A0 (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
AU3078892A (en) Human interleukin-8 analogs
BR0211186A (pt) peptìdeos e uso dos mesmos no escurecimento da pele
CA2106215A1 (en) Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
RU94037764A (ru) Фармацевтические бактериоциновые композиции и их применение
ATE103776T1 (de) Neue n-(sulfomethyl)-n'-arylharnstoffe.
ES2087337T3 (es) Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos.
DK1431391T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
DE69312319D1 (de) Tachyquinin antagonisten, ihre herstellung und ihre verwendung in pharmazeutischen formulierungen
DK0554634T3 (da) Stabiliseret farmaceutisk præparat af ikke-glycosyleret humant recombinant interleukin-2 i reduceret form
ATE208627T1 (de) Orale zusammensetzungen mit niedrigdosierten zytotoxischen proteinen
HUP0000812A2 (hu) Myelin bázikus fehérje peptid-fragmentumai az azokat tartalmazó gyógyszerkészítmények és felhasználásuk a sclerosis multiplex kezelésére
CA2247998A1 (en) Fragments of cr1 and their use
ATE239499T1 (de) Protein-disulfid-isomerasen enthaltende pharmazeutische zusammensetzungen
CA2153071A1 (en) Derivatized calcitonins